Editing Anticoagulant (section)

=== Utilization ===
Research has been conducted on changes in anticoagulant drug supply for hospitals in the US during the COVID-19 pandemic from 2018–2022. According to researchers, "there was a 43.4% decline in the total volume of anticoagulants and antiplatelets at US hospitals in March 2020, driven by a decrease in heparin volume."<ref>{{Cite journal |last=Wong |first=Paul J |last2=Mosley |first2=Scott A |last3=Ng |first3=Tien M H |last4=Shooshtari |first4=Andrew |last5=Alexander |first5=G Caleb |last6=Qato |first6=Dima M |date=2022-12-26 |title=Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018–2021) |url=https://doi.org/10.1093/ajhp/zxac381 |journal=American Journal of Health-System Pharmacy |volume=80 |issue=11 |pages=692–98 |doi=10.1093/ajhp/zxac381 |issn=1079-2082}}</ref> Furthermore, it has been found that "Therapeutic AC [Anticoagulation] use declined from 32% in 2020 to 12% in 2022, especially after December 2021" and the introduction of the Omicron variant.<ref>{{Cite journal |last=Lee |first=Eileen |last2=Bates |first2=Benjamin |last3=Kuhrt |first3=Nathaniel |last4=Andersen |first4=Kathleen M |last5=Visaria |first5=Aayush |last6=Patel |first6=Rachel |last7=Setoguchi |first7=Soko |last8=the N3C Consortium |last9=Wilcox |first9=Adam B |last10=Lee |first10=Adam M |last11=Graves |first11=Alexis |last12=Anzalone |first12=Alfred (Jerrod) |last13=Manna |first13=Amin |last14=Saha |first14=Amit |last15=Olex |first15=Amy |date=2023-10-03 |title=National Trends in Anticoagulation Therapy for COVID-19 Hospitalized Adults in the United States: Analyses of the National COVID Cohort Collaborative |url=https://academic.oup.com/jid/article/228/7/895/7189198 |journal=The Journal of Infectious Diseases |language=en |volume=228 |issue=7 |pages=895–906 |doi=10.1093/infdis/jiad194 |issn=0022-1899|pmc=10547450 }}</ref>